IGC Pharma (IGC) Other Non-Current Assets (2011 - 2026)

IGC Pharma (IGC) has reported Other Non-Current Assets for 16 consecutive years, with $659000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 3.23% year-over-year to $659000.0 in Q1 2026; TTM through Mar 2026 was $659000.0, a 3.23% decrease from a year earlier, with the FY2026 full-year figure at $659000.0, down 3.23% from the prior year.
• Other Non-Current Assets was $659000.0 for Q1 2026 at IGC Pharma, down from $669000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.0 million in Q4 2022 and troughed at $659000.0 in Q1 2026.
• A 5-year average of $821117.6 and a median of $688000.0 in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets soared 67.97% in 2022 and tumbled 32.35% in 2024, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $1.0 million in 2022, then slipped by 2.82% to $999000.0 in 2023, then plunged by 31.83% to $681000.0 in 2024, then decreased by 1.76% to $669000.0 in 2025, then declined by 1.49% to $659000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $659000.0 (Q1 2026), $669000.0 (Q4 2025), and $672000.0 (Q3 2025), per Business Quant data.